SEARCH:   Advanced

Blood, 15 November 2005, Vol. 106, No. 10, pp. 3594-3601. Prepublished online as a Blood First Edition Paper on August 4, 2005; DOI 10.1182/blood-2005-02-0487. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-02-0487v1 106/10/3594    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Tome, M. E. Articles by Briehl, M. M. Search for Related Content PubMed PubMed Citation Articles by Tome, M. E. Articles by Briehl, M. M. Related Collections Neoplasia Signal Transduction Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis Margaret E. Tome, David B. F. Johnson, Lisa M. Rimsza, Robin A. Roberts, Thomas M. Grogan, Thomas P. Miller, Larry W. Oberley, and Margaret M. Briehl From the Departments of Pathology and Hematology Oncology, University of Arizona, Tucson; and the Department of Radiation Research, University of Iowa, Iowa City. Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease in which approximately 40% of the patients respond well to current chemotherapy, but the prognosis for the other 60% is poor. The Leukemia/Lymphoma Molecular Profiling Project (LLMPP) used microarray technology to define a molecular profile for each of 240 patients with DLBCL and develop a molecular outcome predictor score that accurately predicted patient survival. Data from our laboratory and others suggest that alterations in antioxidant defense enzyme levels and redox environment can be oncogenic and affect the response to glucocorticoid treatment, one of the components of combination chemotherapy regimens for lymphoma. The goal of the current study was to reanalyze the LLMPP microarray data to determine whether the levels of antioxidant defense enzymes and redox proteins were correlated with prognosis in DLBCL. We found that patients with DLBCL with the worst prognosis, according to the outcome predictor score, had decreased expression of catalase, glutathione peroxidase, manganese superoxide dismutase, and VDUP1, a protein that inhibits thioredoxin activity. The data suggest that the patients with the worst prognosis combine a decrease in antioxidant defense enzyme expression with an increase in thioredoxin system function (the redox signature score). CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: F. Turturro, G. Von Burton, and E. Friday Hyperglycemia-Induced Thioredoxin-Interacting Protein Expression Differs in Breast Cancer-Derived Cells and Regulates Paclitaxel IC50 Clin. Cancer Res., June 15, 2007; 13(12): 3724 - 3730. [Abstract] [Full Text] [PDF] C. Andreadis, P. A. Gimotty, P. Wahl, R. Hammond, J. Houldsworth, S. J. Schuster, and T. R. Rebbeck Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma Blood, April 15, 2007; 109(8): 3409 - 3416. [Abstract] [Full Text] [PDF] K. Reue and L. Vergnes Thematic review series: Systems Biology Approaches to Metabolic and Cardiovascular Disorders. Approaches to lipid metabolism gene identification and characterization in the postgenomic era J. Lipid Res., September 1, 2006; 47(9): 1891 - 1907. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020